Takeda to buy UK's Paradigm Therapeutics

19 March 2007

Japanese drugmaker Takeda says that it will acquire UK-based drug discovery and development firm Paradigm Therapeutics. Takeda explained that the acquisition, which is expected to complete in a few weeks, builds on the pre-existing alliance between the two firms, which is focused on the creation of treatments for diseases of the central nervous system (Marketletters passim).

Takeda said that the merger, financial details of which were not provided, would see the integration of technologies and research staff from Paradigm's sites in both the UK and Singapore, into its target validation and genomic research operations.

The Osaka-headquarterered firm added that, through the deal, it would gain the UK company's promising drug pipeline, which includes developmental treatments for a range of disorders including pain, prostate and breast cancer, diabetes, hyperlipidemia and obesity.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight